QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ ...

Core News & Articles

Item 1.01 Entry into a Material Definitive Agreement On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (t...

Core News & Articles

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkin...

Core News & Articles

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $15 pr...

Core News & Articles

SATS: 92% | EchoStar To Sell 3.45 GHz And 600 MHz Spectrum Licenses To AT&T For $23B, Establishes Hybrid MNO Agreement With...

Core News & Articles

Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ ...

Core News & Articles

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Serina Therapeutics (AMEX:SER) with a Buy rating an...

Core News & Articles

Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION